BeneFIX Drug Use Results Survey [All-Case Surveillance]

CompletedOBSERVATIONAL
Enrollment

314

Participants

Timeline

Start Date

October 29, 2009

Primary Completion Date

August 29, 2014

Study Completion Date

February 27, 2017

Conditions
Hemophilia B
Interventions
DRUG

Nonacog Alfa (Genetical Recombination)

"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."

Trial Locations (1)

Unknown

Tokyo Medical University Hospital, Shinjuku-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY